In today’s episode Ginger Vieria is joined by Diana Isaacs, PharmD, and Endocrine Clinical Pharmacist, to dive deeper into the pharmacokinetics and pharmacodynamics of long-acting insulin.They explore how long-acting insulin can improve blood glucose levels, reduce the burden of daily injections, and simplify insulin management for the person with diabetes.Diana Isaacs is a diabetes advocate and speaker. She’s a Director in Education & Training in Diabetes Technology at the Cleveland Clinic, and she’s also a Fellow of the Association of Diabetes Care and Education Specialists (FADCES) and the American College of Clinical Pharmacy (FCCP).If you’d like to dive deeper into today’s topic, don’t miss our CME/CPD accredited e-learning course, titled Breaking New Ground: Once-Weekly Insulin. The session delves into the evolution of long-acting insulin therapy and introduces groundbreaking once-weekly formulations. 1 CME/CPD Credit available.Make sure you’re subscribed to the ATTD Podcast feed today. Leave us a review and share with a colleague.
--------
29:59
--------
29:59
Introduction to Long-Acting Insulin Therapy
In the first episode of ATTD’s brand new series on long-acting insulin, join our host Ginger Vieira and guest Jennifer Okemah, RD, CDCES, as they provide an overview of the role of long-acting insulin in diabetes management, the potential benefits, and the evolution of the different formulations available today.Jennifer Okemah has been a Registered Dietitian (RD)/Nutritionist since 2005 and a Certified Diabetes Care and Education Specialist (CDCES) since 2007.She has an additional certification as a Sports Specialist in Dietetics as well as being Board Certified in Advanced Diabetes Management.Explore more on the ATTD Education Portal. Register now to access exclusive content and stay ahead in the field!Make sure you’re subscribed to the ATTD Podcast feed today. Leave us a review and share with a colleague.
What’s next in long-acting insulin therapy? Find out in ATTD Diabetes Talks: Long-Acting Insulin Uncovered, a new podcast for healthcare professionals who want to stay ahead in diabetes care.Hosted by Ginger Vieira and powered by ATTD, this series brings you real conversations with CDCESs, PharmDs, pediatric endocrinologists, and people living with diabetes.We’ll dive into the latest trends, explore clinical benefits, discuss patient selection strategies, and share real-world success stories to help you apply new insights in your practice.Subscribe now and join us as we uncover how long-acting insulin is shaping the future of diabetes management.
--------
2:11
--------
2:11
Toward the Cure of Type 1 Diabetes, ATTD 2025 Conference Catch-Up
In this episode of ATTD 2025 Conference Catch-Up, we dive into Toward the Cure of Type 1 Diabetes, featuring exciting discussions on cutting-edge strategies, from gene therapy to biomaterials, aimed at advancing beta cell replacement and ultimately finding a cure for type 1 diabetes.Join us as we summarize key takeaways from these thought-provoking presentations:Biomaterials to Aid Beta Cell Replacement - Current and Future Perspectives – Dr. Victoria SalemNew Strategies for Curative Therapies for Diabetes – Prof. Stefan BornsteinUpdate on Efforts to Interdict Type 1 Diabetes – Dr. Desmond SchatzThis episode is an essential listen for endocrinologists, diabetes researchers, clinicians, and healthcare professionals interested in the latest advances in curative therapies, including gene therapy, biomaterials, and novel treatments aimed at reversing type 1 diabetes.Enjoy the listen!This podcast was created using AI to provide a quick and insightful summary of an ATTD 2025 session. While every effort has been made to ensure accuracy, listeners are encouraged to refer to original conference materials and recordings for detailed information.ATTD 2025, the 18th International Conference on Advanced Technologies & Treatments for Diabetes, is taking place on March 19-22, 2025, in Amsterdam.https://attd.kenes.com
--------
28:41
--------
28:41
Time in Tight Range: Primary Treatment Goal in Diabetes, ATTD 2025 Conference Catch-Up
In this episode of ATTD 2025 Conference Catch-Up, we dive into View, Counterview: Time in Tight Range Should Be the Primary Treatment Goals and Outcome Measure in Diabetes, featuring a lively debate on the role of time in tight range as a primary treatment goal, weighing the benefits of advanced CGM technology against the potential psychological and practical challenges.Join us as we summarize key takeaways from these thought-provoking presentations:View – Dr. Anders CarlsonCounterview – Dr. Jeremy Pettus Rebuttal by Speaker Presenting View – Dr. Anders CarlsonRebuttal by Speaker Presenting Counterview – Dr. Jeremy PettusThis episode is an essential listen for endocrinologists, diabetes specialists, and healthcare professionals looking to explore the role of tight glycemic control in diabetes management, understand the advantages and challenges of using time in range as an outcome measure, and gain insight into the evolving landscape of diabetes care.Enjoy the listen!This podcast was created using AI to provide a quick and insightful summary of an ATTD 2025 session. While every effort has been made to ensure accuracy, listeners are encouraged to refer to original conference materials and recordings for detailed information.ATTD 2025, the 18th International Conference on Advanced Technologies & Treatments for Diabetes, is taking place on March 19-22, 2025, in Amsterdam.https://attd.kenes.com
Sobre ATTD: Advanced Technologies and Treatments for Diabetes
ATTD is the ultimate forum for the latest in diabetes research, technology, and clinical innovation. This podcast channel offers two types of content designed for busy healthcare professionals:
* ATTD Conference Catch-up: Short, AI-generated episodes with key insights from expert presentations and research discussions at the ATTD Conference.
* Curated Series: In-depth, human-led conversations on topics like Long-Acting Insulin Uncovered, featuring expert interviews and real-world stories, supported by Eli Lilly.
Whether you're a specialist, researcher, or industry leader, hit subscribe.